Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Thessaly | OTHER |
| Aristotle University Of Thessaloniki | OTHER |
| Metaxa Hospital | OTHER |
| Saint Savvas Anticancer Hospital |
Not provided
Not provided
Not provided
Enhanced Recovery After Surgery (ERAS) are developed to provide a systematic structure for managing postsurgical patients.These protocols promote evidenced-based practices and implement a multidisciplinary effort to maintain normal physiology in the perioperative period and aid in earlier recovery. The present study aims to investigate the feasibility of and compliance to a structured ERAS protocol among Gynecological Oncological Centers in Greece as well as to compare the outcomes among patients that fullfilled the minimum number of necessary criteria, compared to those that were enrolled in ERAS protocols but did not meet the sufficient necessary criteria.
Enhanced Recovery After Surgery (ERAS) are developed to provide a systematic structure for managing postsurgical patients.These protocols promote evidenced-based practices and implement a multidisciplinary effort to maintain normal physiology in the perioperative period and aid in earlier recovery. ERAS protocols briefly include pre-admission education, pre-operative nutritional care, specific recommendations for pre-operative medications, a standardized anesthetic protocol, perioperative fluid management, multimodal analgesia (MMA), early mobilization, and early removal of urinary catheters.
ERGO study study aims to investigate the feasibility of and compliance to a structured ERAS protocol among Gynecological Oncological Centers in Greece as well as to compare the outcomes among patients that fullfilled the minimum number of necessary criteria, compared to those that were enrolled in ERAS protocols but did not meet the sufficient necessary criteria. Patients will be registered into the trial before surgery. Quality assurance program will be in place for both patients that will fulfill the ERAS criteria as well as for those that will not fulfill them.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fulfilled ERAS criteria group | This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols. |
| |
| Control group | This group will include patients that achieved a compliance rate that did not reach at least 80% of the required predetermined criteria of ERAS protocols. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ERAS group | Combination Product | This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Duration of hospitalization | From date of hospitalization until the date of discharge or date of death from any cause, whichever came first, assessed up to 2 months. | Up to 30 days postoperatively |
| Perioperative infections | Number of participants with postoperative infections (including surgical site, pulmonary and urinary tract infections) | Postoperatively (30 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative quality of life | Documentation of quality of life using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C40) and the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires. The EORTC-QLQ C30 involves 30 questions that are rated from 1 (no impact on quality of life) to 4 (debilitating symptoms). The FACT-G assesses physical, family, emotional and functional wellbeing through 27 questions that are scaled from 0 (no impact) to 4 (very much). |
Not provided
Inclusion Criteria:
patients with gynaecological cancer and an ECOG performance status <4, ASA score <4.
Exclusion Criteria:
patients with metastatic cancer of non-gynaecological origin patients that are not able to follow ERAS protocol due to medical reasons patients with severe debilitating comorbidities (ECOG status 4, ASA score 4-5)
Participant eligibility is not based on self-representation
In this study, patients that will be operated for gynecological cancer in the collaborating centers described in the Contacts and Locations section will be enrolled.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nikolaos Thomakos, MD, PhD | Contact | +302132162291 | thomakir@hotmail.com | |
| Vasilios Pergialiotis, MD, PhD, MSc | Contact | +302132162291 | pergialiotis@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| First department of Obstetrics and Gynecology | Recruiting | Athens | Athens | 11523 | Greece |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37652530 | Background | Pandraklakis A, Haidopoulos D, Lappas T, Stamatakis E, Valsamidis D, Oikonomou MD, Loutradis D, Rodolakis A, Bisch SP, Nelson G, Thomakos N. Thoracic epidural analgesia as part of an enhanced recovery program in gynecologic oncology: a prospective cohort study. Int J Gynecol Cancer. 2023 Nov 6;33(11):1794-1799. doi: 10.1136/ijgc-2023-004621. | |
| 33139130 |
Not provided
Not provided
IPD will be provided upon reasonable request following communication with researchers
Following study completion and up to 5 years from publication of findings.
Data will be provided through a dedicated de-identified redcap database
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D007239 | Infections |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
| Control group | Combination Product | This group will include patients that do not follow the predetermined criteria of ERAS protocols |
|
| Postoperatively (30 days) |
| Postoperative morbidity (other than infectious) using the Clavien-Dindo classification | Major events such as pulmonary embolism,accuse myocardial infarction,etc | 30 days |
| Interval to adjuvant therapy | The interval between surgical treatment and adjuvant therapy (radiation and/or chemotherapytreatment) will be documented | Up to 100 days |
| Recurrence rates | Recurrent disease will be monitored through 3 year of follow up | 3 years follow-up |
| Overall survival | Overall survival of the patients will be measured through 3 year of follow up | 3 years follow-up |
| Agios Savvas Anticancer Hospital | Recruiting | Athens | Attica | 11522 | Greece |
|
| First department of Obstetrics and Gynecology, National and Kapodistrian University of Athens | Recruiting | Athens | Attica | 11528 | Greece |
|
| University of Thessaly | Recruiting | Larissa | Larissa | 413 34 | Greece |
|
| Metaxa Anticancer Hospital | Not yet recruiting | Athens | Piraeus | 18537 | Greece |
|
| Aristotle University of Thessaloniki, Second department of Obstetrics and Gynecology | Recruiting | Thessaloniki | Thessaloniki | 54642 | Greece |
|
| Aristotle University of Thessaloniki, Third department of Obstetrics and Gynecology | Recruiting | Thessaloniki | Thessaloniki | 54642 | Greece |
|
| Aristotle University of Thesalloniki, Papageorgiou Hospiral | Recruiting | Thessaloniki | Thessaloniki | 56429 | Greece |
|
| Bogani G, Sarpietro G, Ferrandina G, Gallotta V, DI Donato V, Ditto A, Pinelli C, Casarin J, Ghezzi F, Scambia G, Raspagliesi F. Enhanced recovery after surgery (ERAS) in gynecology oncology. Eur J Surg Oncol. 2021 May;47(5):952-959. doi: 10.1016/j.ejso.2020.10.030. Epub 2020 Oct 28. |
| 37490193 | Background | Nelson G. Enhanced Recovery in Gynecologic Oncology Surgery-State of the Science. Curr Oncol Rep. 2023 Oct;25(10):1097-1104. doi: 10.1007/s11912-023-01442-0. Epub 2023 Jul 25. |
| 37086524 | Background | Nelson G, Fotopoulou C, Taylor J, Glaser G, Bakkum-Gamez J, Meyer LA, Stone R, Mena G, Elias KM, Altman AD, Bisch SP, Ramirez PT, Dowdy SC. Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update. Gynecol Oncol. 2023 Jun;173:58-67. doi: 10.1016/j.ygyno.2023.04.009. Epub 2023 Apr 21. |
| 32753562 | Background | Bhandoria GP, Bhandarkar P, Ahuja V, Maheshwari A, Sekhon RK, Gultekin M, Ayhan A, Demirkiran F, Kahramanoglu I, Wan YL, Knapp P, Dobroch J, Zmaczynski A, Jach R, Nelson G. Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice. Int J Gynecol Cancer. 2020 Oct;30(10):1471-1478. doi: 10.1136/ijgc-2020-001683. Epub 2020 Aug 4. |
| 41463241 | Derived | Pergialiotis V, Haidopoulos D, Daponte A, Tsolakidis D, Petousis S, Kalogiannidis I, Vlachos DE, Lygizos V, Fanaki M, Delinasios G, Tzitzis P, Ntailianas P, Theodoulidis V, Margioula Siarkou G, Daponte N, Thomakos N. Implementation Rates and Predictors of Compliance with Enhanced Recovery After Surgery Protocols in Gynecologic Oncology: A Prospective Multi-Institutional Cohort Study. Cancers (Basel). 2025 Dec 15;17(24):3991. doi: 10.3390/cancers17243991. |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D008722 | Methods |